Clinical observation on efficacy of Edaravone in treatment of 53 patients with acute cerebral infarction

Objective To evaluate the efficacy and adverse reactions of Edaravone in treatment of acute cerebral infarction(ACI).Methods A randomized controlled study was carried out in treatment of 100 patients with ACI enrolled within 24 hours of onset,they were randomly allocated into treatment group(n =53)and control group(n =47).Patients in both groups were given Xuesaitong Injection and aspirin 50～75 mg orally once per day.Patients in treatment group also received Edaravone injection 30 mg twice per day for 14 days.The neurological deficits and activities of daily living(ADL)of patients in both groups were assessed by using Chinese Stroke Scale(CSS)and Barthel Index respectively before and after the treatment.Clinical efficacy was evaluated according to changes of CSS and ADL scores on the 21th day.Results The efficacy rates in treatment group and control group were 84.9% and 68.1% respectively(P0.05).There was a significant difference in CSS scores and ADL scores between treatment group and control group(P0.05).There was no distinct adverse reaction seen in these two groups.Conclusion Edaravone can improve impaired neurological function and activities of daily living in patients with acute cerebral infarction without obviously adverse reaction.Edaravone is effective and safe in treatment of patients with acute cerebral infarction.It is worthy to be recommended for clinical application.